Literature DB >> 27974468

Dysregulation of CUL4A and CUL4B Ubiquitin Ligases in Lung Cancer.

Lei Jia1, Fan Yan1,2, Wenfeng Cao3, Zhengming Chen4, Hong Zheng5, Haixin Li5, Yi Pan3, Navneet Narula2, Xiubao Ren6, Hui Li7,8, Pengbo Zhou9,2.   

Abstract

The Cullin-RING ubiquitin ligase 4 (CRL4) is implicated in controlling cell cycle, DNA damage repair, and checkpoint response based on studies employing cell lines and mouse models. CRL4 proteins, including CUL4A and CUL4B, are often highly accumulated in human malignancies. Elevated CRL4 attenuates DNA damage repair and increases genome instability that is believed to facilitate tumorigenesis. However, this has yet to be evaluated in human patients with cancer. In our study, 352 lung cancer and 62 normal lung specimens of Asian origin were constructed into tissue microarrays of four distinct lung cancer subtypes. Expression of CUL4A, CUL4B, and their substrates was detected by immunohistochemistry and analyzed statistically for their prognostic value and association with DNA damage response and genomic instability. Our results show that both CUL4A and CUL4B are overexpressed in the majority of lung carcinomas (PCUL4A <0.001 and PCUL4B <0.001) and significantly associated with tumor size (PCUL4A <0.001 and PCUL4B = 0.002), lymphatic invasion (PCUL4A = 0.004 and PCUL4B <0.001), metastasis (PCUL4A = 0.019 and PCUL4B = 0.006), and advanced TNM stage (PCUL4A <0.001 and PCUL4B <0.001), which parallels gene amplification and abnormal activation of the canonical WNT signaling. Moreover, overexpression of CUL4A, but not CUL4B, is significantly associated with tobacco smoking (p = 0.01) and is inversely correlated with XPC and P21, both of which are substrates of CUL4A (PCUL4A = 0.019 and PCUL4B = 0.006). Higher levels of CUL4A or CUL4B are significantly associated with the overall survival of patients (PCUL4A <0.001 and PCUL4B <0.001) and progression-free survival (PCUL4A <0.001 and PCUL4B = 0.001). Our findings revealed that CUL4A and CUL4B are differentially associated with etiologic factors for pulmonary malignancies and are independent prognostic markers for the survival of distinct lung cancer subtypes.
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  E3 ubiquitin ligase; cell signaling; immunohistochemistry; lung cancer; protein degradation; ubiquitin; ubiquitin ligase

Mesh:

Substances:

Year:  2016        PMID: 27974468      PMCID: PMC5314191          DOI: 10.1074/jbc.M116.765230

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

1.  Involvement of CUL4 ubiquitin E3 ligases in regulating CDK inhibitors Dacapo/p27Kip1 and cyclin E degradation.

Authors:  Leigh Ann Higa; Xiaoming Yang; Jianyu Zheng; Damon Banks; Min Wu; Papia Ghosh; Hong Sun; Hui Zhang
Journal:  Cell Cycle       Date:  2006-01-21       Impact factor: 4.534

2.  The E3 ubiquitin ligase Cullin 4A regulates meiotic progression in mouse spermatogenesis.

Authors:  Yan Yin; Congxing Lin; Sung Tae Kim; Ignasi Roig; Hong Chen; Liren Liu; George Michael Veith; Ramon U Jin; Scott Keeney; Maria Jasin; Kelle Moley; Pengbo Zhou; Liang Ma
Journal:  Dev Biol       Date:  2011-05-23       Impact factor: 3.582

3.  Quantitative analysis of p53 expression in human normal and cancer tissue microarray with global normalization method.

Authors:  Halliday A Idikio
Journal:  Int J Clin Exp Pathol       Date:  2011-06-15

4.  Cullin 4A associates with the UV-damaged DNA-binding protein DDB.

Authors:  P Shiyanov; A Nag; P Raychaudhuri
Journal:  J Biol Chem       Date:  1999-12-10       Impact factor: 5.157

Review 5.  CUL4B-deficiency in humans: understanding the clinical consequences of impaired Cullin 4-RING E3 ubiquitin ligase function.

Authors:  Claudia Kerzendorfer; Lesley Hart; Rita Colnaghi; Gillian Carpenter; Diana Alcantara; Emily Outwin; Antony M Carr; Mark O'Driscoll
Journal:  Mech Ageing Dev       Date:  2011-02-23       Impact factor: 5.432

6.  High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer.

Authors:  R M Bremnes; R Veve; E Gabrielson; F R Hirsch; A Baron; L Bemis; R M Gemmill; H A Drabkin; W A Franklin
Journal:  J Clin Oncol       Date:  2002-05-15       Impact factor: 44.544

7.  TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas.

Authors:  Kohichiroh Yasui; Shigeki Arii; Chen Zhao; Issei Imoto; Masakazu Ueda; Hisaki Nagai; Mitsuru Emi; Johji Inazawa
Journal:  Hepatology       Date:  2002-06       Impact factor: 17.425

8.  CUL-4 ubiquitin ligase maintains genome stability by restraining DNA-replication licensing.

Authors:  Weiwei Zhong; Hui Feng; Fernando E Santiago; Edward T Kipreos
Journal:  Nature       Date:  2003-06-19       Impact factor: 49.962

9.  Diversification of the cullin family.

Authors:  Ignacio Marín
Journal:  BMC Evol Biol       Date:  2009-11-19       Impact factor: 3.260

10.  Smoking cessation reverses DNA double-strand breaks in human mononuclear cells.

Authors:  Mari Ishida; Takafumi Ishida; Satoshi Tashiro; Hitomi Uchida; Chiemi Sakai; Naoya Hironobe; Katsuya Miura; Yu Hashimoto; Koji Arihiro; Kazuaki Chayama; Yasuki Kihara; Masao Yoshizumi
Journal:  PLoS One       Date:  2014-08-05       Impact factor: 3.240

View more
  21 in total

1.  The E3 ubiquitin ligase Cul4b promotes CD4+ T cell expansion by aiding the repair of damaged DNA.

Authors:  Asif A Dar; Keisuke Sawada; Joseph M Dybas; Emily K Moser; Emma L Lewis; Eddie Park; Hossein Fazelinia; Lynn A Spruce; Hua Ding; Steven H Seeholzer; Paula M Oliver
Journal:  PLoS Biol       Date:  2021-02-01       Impact factor: 8.029

2.  CUL4B regulates autophagy via JNK signaling in diffuse large B-cell lymphoma.

Authors:  Ying Li; Xiangxiang Zhou; Ya Zhang; Juan Yang; Yangyang Xu; Yi Zhao; Xin Wang
Journal:  Cell Cycle       Date:  2019-02-01       Impact factor: 4.534

3.  CpG-binding protein CFP1 promotes ovarian cancer cell proliferation by regulating BST2 transcription.

Authors:  Liu-Qing Yang; Han-Yin Hu; Yao Han; Ze-Yi Tang; Jie Gao; Qi-Yin Zhou; Yi-Xuan Liu; Hao-Sa Chen; Tu-Nan Xu; Lei Ao; Ying Xu; Xuan Che; Ya-Bo Jiang; Chun-Wei Xu; Xian-Chao Zhang; Yu-Xin Jiang; Michal Heger; Xiao-Min Wang; Shu-Qun Cheng; Wei-Wei Pan
Journal:  Cancer Gene Ther       Date:  2022-07-21       Impact factor: 5.854

4.  DCAF13 promotes pluripotency by negatively regulating SUV39H1 stability during early embryonic development.

Authors:  Yin-Li Zhang; Long-Wen Zhao; Jue Zhang; Rongrong Le; Shu-Yan Ji; Chuan Chen; Yawei Gao; Dali Li; Shaorong Gao; Heng-Yu Fan
Journal:  EMBO J       Date:  2018-08-14       Impact factor: 11.598

Review 5.  Chromatin-Bound Cullin-Ring Ligases: Regulatory Roles in DNA Replication and Potential Targeting for Cancer Therapy.

Authors:  Sang-Min Jang; Christophe E Redon; Mirit I Aladjem
Journal:  Front Mol Biosci       Date:  2018-03-13

Review 6.  The role of cullin4B in human cancers.

Authors:  Ying Li; Xin Wang
Journal:  Exp Hematol Oncol       Date:  2017-06-15

7.  Cul4B promotes the progression of ovarian cancer by upregulating the expression of CDK2 and CyclinD1.

Authors:  Peng-Jing Duan; Juan-Hong Zhao; Li-Li Xie
Journal:  J Ovarian Res       Date:  2020-07-04       Impact factor: 4.234

Review 8.  The emerging role for Cullin 4 family of E3 ligases in tumorigenesis.

Authors:  Ji Cheng; Jianping Guo; Brian J North; Kaixiong Tao; Pengbo Zhou; Wenyi Wei
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-12-30       Impact factor: 10.680

Review 9.  Key regulators of sensitivity to immunomodulatory drugs in cancer treatment.

Authors:  Shichao Wang; Zhiyue Li; Shaobing Gao
Journal:  Biomark Res       Date:  2021-06-05

10.  CUL4high Lung Adenocarcinomas Are Dependent on the CUL4-p21 Ubiquitin Signaling for Proliferation and Survival.

Authors:  Yannan Wang; Fan Yan; Abu Nasar; Zhe-Sheng Chen; Nasser Khaled Altorki; Brendon Stiles; Navneet Narula; Pengbo Zhou
Journal:  Am J Pathol       Date:  2021-06-11       Impact factor: 5.770

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.